{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"10"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"146"}],"units":"Participants"}],"description":"To evaluate the incidence of ADAs against JS001","groups":[{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，placebo will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and placebo for up to 2 years","id":"OG000","title":"Placebo Combine With Chemotherapy"},{"description":"Gemcitabine 1000 mg/m² IV are given on Days 1 \\& 8, and cisplatin 80 mg/m² IV are given on Day 1 of each cycle，JS001 will be administered at the dose of 240 mg Q3W before that. Chemotherapy is given Q3W for up to 6 cycles and JS001 for up to2years","id":"OG001","title":"TORIPALIMAB INJECTION(JS001 )Combine With Chemotherapy"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"ADA testing only was applicable for Toripalimab group","reportingStatus":"POSTED","timeFrame":"From date of randomization, until disease progression , loss of clinical benefit ,withdrawal of consent, death, or study termination by the Sponsor, whichever occurs first. Up to 2 approximately years","title":"Anti-drug Antibody(ADA)","type":"SECONDARY","unitOfMeasure":"Participants"}